Medical devices, healthcare technology and the business of care
PMA approval · P220021

DETOUR System

Endologix, LLC · Decision date Jun 7, 2023

MEDTECHLEDGER EXPLANATIONP220021

What did the FDA approve?

The FDA entry P220021 records an approval decision dated June 7, 2023, for the DETOUR System from Endologix, LLC, under product code QWM, device category "Stent graft, bypass, superficial femoral artery," specialty Cardiovascular, with decision status APPR. The statement describes the approved use as percutaneous revascularization in patients with symptomatic femoropopliteal lesions from 200 mm to 460 mm in length with chronic total occlusions (100 mm to 425 mm) or diffuse stenosis >70% who may be considered suboptimal candidates for surgical or alternative endovascular treatments.

The record identifies this as an original approval rather than a supplement, so no prior PMA relationship is established by the identifier. The statement also excludes use in the coronary and cerebral vasculature. It reports the approved indication and its length and occlusion thresholds; it does not present trial data, adverse-event rates, or independent demonstration of safety or clinical effectiveness, and the supplied fields do not add such evidence.

FDA approval order statement

Approval for the DETOUR System for use for percutaneous revascularization in patients with symptomatic femoropopliteal lesions from 200 mm to 460 mm in length with chronic total occlusions (100 mm to 425 mm) or diffuse stenosis >70% who may be considered suboptimal candidates for surgical or alternative endovascular treatments. The DETOUR System, or any of its components, is not for use in the coronary and cerebral vasculature.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Jun 7, 2023

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P220021
Regulatory pathway
Premarket approval application
Product code
QWM
Decision code
APPR
Decision date
Jun 7, 2023
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stent graft, bypass, superficial femoral artery.

Product code
QWM
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P220021 received

    Application receipt date recorded by FDA.

  2. P220021 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P220021. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P220021

Product / regulatory recordCompanyPathwayDecision dateSource
DETOUR SystemP220021/S009
Endologix, LLCPMA supplementOct 16, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Endologix, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
3910 Brickway Blvd., Santa Rosa, CA, 95403

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records